Q1 FY27 results: consolidated revenue up 163%, PAT up 133% YoY; share swap approved

Revenue Growth 20pctPat Growth 25pctEbitda Margin ExpansionResults View source PDF Explain this filing

AHCL · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

-8.1%1-day move

₹15.90

prior close

₹15.16

base price

In-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

-4.0-3.6-2.7-3.1-8.1-7.2-8.2-8.4-11.1-9.1-9.6———

Up moveDown movePending

AI summary

Anlon Healthcare Board approved Q1 FY27 (ended June 30, 2026) results. Standalone revenue fell 7% to Rs 3,097.56 lakhs but PAT rose 35% to Rs 479.71 lakhs. Consolidated revenue jumped 163% to Rs 8,756.27 lakhs and PAT grew 133% to Rs 828.14 lakhs on subsidiary contributions. Board also approved a share swap to acquire Apiqo Organics (32.52%) and Bizotic LifeScience (43.33%) via preferential equity, making them wholly owned subsidiaries. IPO proceeds fully utilized. Auditor issued a clean review.

Likely market impact

Strong consolidated growth driven by subsidiaries. Share swap will dilute existing shareholders but consolidates two units as wholly owned.